In the bio for Bridgette J. Picou, LVN, ACLPN, stakeholder liaison, The Well Project, Brooklyn, New York, it states, “Sitting at the intersections of being Black, a woman, and living with HIV, her goal is to remind people that there […]
Bridgette J. Picou, LVN, ACLPN Read More »
Each year, May is recognized as National Women’s Health Month—or alternatively, Women’s Health Awareness Month—with the week beginning on Mother’s Day observed as National Women’s Health Week. For 2025, as designated by HHS, the theme for this awareness month is,
5 Rare Disorders Named for Pioneering Female Scientists Read More »
In a recent interview with The American Journal of Managed Care®, Marla Black Morgan, MD, neurologist with Phoebe Neurology Associates, discussed the findings from her investigation into the diagnostic journeys of patients with rare neuromuscular conditions. She presented findings from
Barriers to Timely Diagnosis of Generalized Myasthenia Gravis: Marla Black Morgan, MD Read More »
The phase 1 ALPHA (NCT03939026) and phase 1/2 ALPHA2 (NCT04416984) trials are investigating cemacabtagene ansegedleucel (cema-cel), an allogeneic chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory large B-cell lymphoma. Findings from these 2 trials comprise the foundation for the phase
MRD Status Guides Consolidation With Cema-Cel in ALPHA3 Trial: Fred Locke, MD Read More »
An analysis comparing estimated out-of-pocket (OOP) costs in 2023 and 2026 for patients with Medicare Part D prescription drug coverage—before and after 3 cost-reducing provisions took effect—found that the Medicare Prescription Payment Plan (MPPP) may help patients maximize their savings
Specialty Drug Users to Gain Relief Under Medicare Reforms Read More »
On May 9, Japan’s Pharmaceuticals and Medical Devices Agency followed the European Union’s lead in approving rozanolixizumab (Rystiggo; UCB) for generalized myasthenia gravis via self-administration.1,2 Patients in the country now have the option to use a manual push or syringe
Rozanolixizumab for gMG Approved in Japan for Self-Administration Read More »
With the current standard of care to direct treatment for pulmonary arterial hypertension (PAH) being invasive thermodilution during right heart catheterization, additional methods are needed for routine risk assessment of these patients. A recent analysis of 93 patients with pulmonary
Impedance Cardiography Offers Noninvasive Insight Into PAH Progression Read More »
In February, the FDA approved a novel triplet combination for relapsed/refractory large B-cell lymphoma, a type of non-Hodgkin lymphoma, based on data from the ongoing phase 3 ECHELON-3 trial (NCT04404283), in which patients have been randomized 1:1 to receive brentuximab
Future Research Priorities for Non-Hodgkin Lymphomas: Craig A. Portell, MD Read More »
Nipocalimab (Imaavy; Johnson & Johnson) was approved by the FDA on April 30, 2025, to treat generalized myasthenia gravis in adult patients and pediatric patients 12 years or older who are anti–acetylcholine receptor (AChR) positive or anti–muscle-specific kinase (MuSK) antibody
In the Concurrent Resolution on the Budget for Fiscal Year 2025 (H Con Res 14, 119th Congress), which the House Committee on Energy and Commerce released late Sunday evening, 160 pages of the bill detail extensive cuts to Medicaid and
Proposed GOP Medicaid Cuts Threaten Loss of Coverage for Millions Read More »
